I thought I’d share the following PQ with you, which you might find of interest. It shows the number of patients who have successfully received treatments on the Cancer Drug Fund (CDF) between April 2011 and February 2012 which are being reviewed / have not been recommended by NICE. It states that 56 patients have received dasatinib, though this of course does not tell us how many applications were made and includes the time period when, before a negative recommendation, dasatinib should have been available for the NHS to prescribe without going through the CDF.

The original PQ is available here.

Dr Poulter: To ask the Secretary of State for Health which drugs have been funded through the Cancer Drugs Fund since its creation; and how many patients have received each drug. [109639]

Mr Simon Burns: Information on the drugs funded under the Cancer Drugs Fund and the number of patients who have received these drugs (from April 2011 to the end of February 2012) is shown in the table. Final figures for 2011-12, based on the final accounts, are expected to be available by the end of June.

Drug (Number of patients funded from April 2011 to end February 2012(*))

Abiraterone (1,010)
Abraxane (49)
Alemtuzumab (49)
Arsenic trioxide (4)
Azacitidine (131)
Bendamustine (373)
Bendamustine and Rituximab (28)
Bevacizumab (2,770)
Bexraotene (3)
Bortezomib (210)
Brentuximab (11)
Cabazitaxel (139)
Capecitibine (5)
Cetuximab (1,132)
Clofarabine (25)
Clofarabine and Daunoxome (1)

Dasatinib (56)

Degarelix (1)
Denosumab (21)
Depocyte (6)
Docetaxel (7)
Doxorubicin (1)
Eribulin (268)
Erlotinib (130)
Everolimus (578)
Folfox (28)
Fulvestrant (333)
Gemcitabine and Methylprednisolone (1)
Gemcitibine (2)
Gliadel Wafer (2)
Hyperthermic Mitomycin (1)
Imatinib (64)
Interferon (2)
Ipilimumab (132)
Irinotecan (1)
Lapatinib (601)
Lapatinib and paclitaxel (2)
Lapatinib with carboplatin (1)
Lenalidomide (71)
Liposomal Doxorubicin (15)
Lutetium Octreotate (10)
Metaidobenzylguanidine (2)
Mifamurtide (13)
Mitotane (5)
Nelarabine (5)
Nilotinib (58)
Ofatumumab (34)
Not specified (39)
Panitimumab (55)
Pazopanib (44)
PEG Asparaginase (3)
Peginterferon Alpha (3)
Pegylated liposomal doxorubicin in combination with carboplatin (14)
Pemetrexed (64)
Rituximab (547)
Sirolimus (2)
Yttrium (90)
Selective Internal Radiation Therapy (39)
Sorafenib (484)
Sorafenib and Clofarabine (2)
Sunitinib (94)
Temozolomide (4)
Temsirolimus (60)
Thiotepa (1)
Topotecan (10)
Trabectedin (3)
Trastuzumab (18)
Velcade (1)
Vinflunine (18)
Vorinostat (1)
Zevalin (2)

Total (9,899)

* Levels of current activity are likely to be higher than these figures suggest, due to the gap between treatment being provided and payment being invoiced and processed. Source: Information supplied to the Department by strategic health authorities.